Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 2

Immunisation against the two human papillomavirus (HPV) genotypes, HPV 16 and 18, found in 70% of cervical cancers, promises a substantial reduction in high-grade cervical intraepithelial neoplasia (CIN) by 67% and cervical cancers by 70%

In the UK, human papillomavirus (HPV) vaccination of girls aged 12–13 years as part of the school immunisation programme started in 2008 together with a three-year ‘catch-up’ programme’ for girls aged up to 18 years. Girls immunised as part of the catch-up cohort have entered the cervical screening programme since 2011 and Scotland is almost uniquely placed to determine the impact of immunisation on cervical HPV infection, incidence of cervical intraepithelial neoplasia and genital warts in young women using national datasets

Source  Art Directors & TRIP / Alamy Stock Photo